DIA Release: Experts To Discuss How Transcelerate Biopharma Collaboration Is Driving Industry Innovation

WASHINGTON--(BUSINESS WIRE)--Andy Lee, MA, Senior Vice President, Head of Global Clinical Trial Operations, Merck & Co., Inc., will chair the late-breaker panel discussion “TransCelerate Collaboration: Harmonization Efforts to Find Solutions to Critical Industry Challenges,” during DIA’s 2015 51^st Annual Meeting at the Walter E. Washington Convention Center from June 14 to 18. Day passes are available for the TransCelerate session via DIA’s website registration page.

“TransCelerate Collaboration: Harmonization Efforts to Find Solutions to Critical Industry Challenges”

Launched in 2012, TransCelerate BioPharma Inc. is a non-profit organization comprised of industry leaders with a mission to improve the health of people around the world by accelerating and enhancing the research and development of innovative new therapies. Through collaboration with the world’s leading biopharmaceutical R&D community, TransCelerate aims to identify, prioritize, design and facilitate the implementation of solutions that drive efficient, effective and high-quality delivery of new medicines. TransCelerate’s growing portfolio of initiatives includes:

• Development of industry-wide clinical data standards
• Mutual recognition of clinical trial-site qualification and training
• Increasing clinical data transparency and diversification
• Creation of a model clinical trial protocol template
• Establishment of a comparator drug network
• Establishment of an innovative Electronic Labels (e-Labels) information channel
• Development of a shared site collaboration platform
• Development of a model approach for risk-based site monitoring

“The TransCelerate panel discussion will provide rich insights and practical solutions to overcoming inefficiencies in clinical trials,” said Barbara Lopez Kunz, DIA’s global chief executive. “We are excited to once again bring together the combined expertise of TransCelerate’s members with key thought leaders from around the globe attending DIA’s Annual Meeting to collaborate on a path forward for streamlining the clinical trial process.”

The June 17 panel, to be held at 1:30 p.m., will examine how TransCelerate’s 21 participating member companies are driving innovation to address clinical trial execution pain points through its 13 initiatives. The session also will address the mission of TransCelerate, what solutions have been delivered to date, and what to expect in 2015 and beyond.

There will be an opportunity for audience Q&A with the panel, which includes members of TransCelerate’s Board of Directors and operations committee. Panelists include Jacalyn Kent, Senior Director, Clinical Development Information & Optimization, Eli Lilly and Company; Brett Wilson, Associate Director, Bristol-Myers Squibb Company; Edward Bowen, MBA, MS, Senior Director, Translational and Bioinformatics, Pfizer Inc.; and Robert A. DiCicco, PharmD, Vice President, Clinical Pharmacology Sciences and Study Operations, GlaxoSmithKline.

ABOUT DIA

For over 50 years, DIA has served as a global platform for more than 30,000 health care product development professionals, researchers, regulators, clinicians, academics and patient advocates to collaborate to improve health globally through the advancement of lifesaving medicines and technologies. As the premier professional community for the health care product development ecosystem, DIA (the Drug Information Association) provides global players a neutral and transparent forum for the exchange of ideas and collaboration. By offering access to tools, resources, and networking opportunities, DIA provides its members and international participants objective opportunities for extending debate and discussion to advance scientific and medical innovation.

DIA is an independent, global nonprofit organization based in Washington, DC, USA, with regional offices representing the Americas (Horsham, PA, USA); Europe, Africa and the Middle East (Basel, Switzerland); and Asia (Beijing, China; Mumbai, India; and, Tokyo, Japan). For more information, visit our website at www.DIAGlobal.org or contact us via Twitter @DrugInfoAssn, LinkedIn or on Facebook.

ABOUT DIA’s 2015 ANNUAL MEETING

The DIA 2015 51^st Annual Meeting brings together a 7,000+ community of life sciences professionals at all levels and across all disciplines from around the globe that are involved in the discovery, development and life cycle management of medical products. Follow Annual Meeting news on Twitter using #DIA2015.